Post-Menopausal Osteopenia Clinical Trials
A listing of Post-Menopausal Osteopenia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Discontinuation of denosumab results in a rebound response of bone turnover markers, which rise above baseline at 3 months and remain elevated until reaching again baseline levels approximately 30 months after the last dose. Bone mineral density (BMD) gains are also lost and BMD values reach original baseline values after …
- 28 views
- 22 Jul, 2021
- 1 location